Net Income
Trailing-twelve-month (TTM) net income is $1.50 Billion with a year-over-year change of (31.06%). Net income represents the company's bottom line profit after all expenses, taxes, and interest.
GEHC Net Income
Reported quarterly net income; no daily interpolation.
GEHC Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 17 quarters.
Net Income (TTM)
$1.50B
$1.50 Billion
Year-over-Year Change
(31.06%)
vs. $2.18B a year ago (TTM)
Net Income CAGR
(31.53%)
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
(31.06%)
3 Year
(7.46%)
5 Year
(31.53%)
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.08B | +$91.00M | +4.57% |
| 2024 | $1.99B | +$425.00M | +27.10% |
| 2023 | $1.57B | ($348.00M) | (18.16%) |
| 2022 | $1.92B | ($331.00M) | (14.73%) |
| 2021 | $2.25B | ($11.60B) | (83.77%) |
| 2020 | $13.85B | +$12.32B | +808.53% |
Net Income Growth Summary
TTM Growth
(31.06%)
3-Year Avg Growth
(7.46%)
5-Year Avg Growth
(31.53%)
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini